Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (198)	12/11/1999 11:10:00 PM
From: Cheryl Galt	Read Replies (3) \| Respond to of 395

Marc, I'm still trying to understand the Parament/Rosenwald connection. Is it terrific, neutral, or something to be concerned about? I've seen no-detail references to Rosenwald by some of our more knowledgeable biotechies, that led me to believe involvement by him could be problematic. So I've been curious. What does the scuttlebut mean? ------------------------ Then I saw a Nov 11 Genta press release that convinced me that Paramount's ability to research investments is exponentially better than mine. With G3139 coming along fast, Genta took on a new CEO and Chairman of the Board. The new chairman is Mark C. Rogers -- with credentials aplenty. "Mark C. Rogers, M.D., MBA, President of Paramount Capital, Inc.,* former CEO of the Duke University Hospital, and a member of Genta's Board of Directors ..."* Read Rogers' Bio at genta.com There's even an Endowed Professorship at Johns Hopkins named for him. I'm impressed enough with his likely power and connections that I'm doubly curious about the Paramount-Capital comments I've noted from time to time on SI. Can anyone fill in some details? Regards, Cheryl